FDA Brief

Warning letters Drugs

FDA warning letter to

ECI Pharmaceuticals, LLC

LowIssued Feb 3, 2022Posted Mar 22, 2022Center for Drug Evaluation and Research | CDER

ECI Pharmaceuticals listed conjugated estrogens instead of esterified estrogens for two drugs, FDA says.

What happened

FDA reviewed ECI Pharmaceuticals’ electronic drug listing information for two esterified estrogens and methyltestosterone products (NDC 51293-639 and 51293-640). FDA found the listing file named conjugated estrogens as an active ingredient while the labeling named esterified estrogens, and it noted earlier deficiency and removal notices dated October 26 and December 10, 2021.

What FDA found

  1. The listing must include the name and quantity of each active ingredient.

    FD&C Act section 510(j)(1)(C), 21 U.S.C. 360
  2. The active ingredient in the electronic listing did not match the active ingredient on the labeling.

    FD&C Act section 510(j); 21 CFR 207
  3. Failure to properly list the drug makes it misbranded.

    FD&C Act section 502(o), 21 U.S.C. 352(o); section 301(a), 21 U.S.C. 331(a)
  4. Failure to meet the listing obligations is a prohibited act.

    FD&C Act section 301(p), 21 U.S.C. 331(p)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter with the specific steps taken, an explanation of steps to prevent recurrence, and related documentation; if corrective actions cannot be completed in that time, the company must state why and when it will finish.

Who should pay attention

  • drug listing and regulatory affairs staff
  • companies with estrogen/methyltestosterone drug listings
  • pharmacies and e-prescribing systems using NDC directory data

This is a summary. Read the original letter on fda.gov.

ECI Pharmaceuticals, LLC's FDA history

  1. ECI Pharmaceuticals, LLC

    FDA warned ECI Pharmaceuticals for listing the wrong active ingredient for its estrogen and testosterone drugs, which got them removed from the NDC Directory.

    Low

Full company page

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk